Literature DB >> 35031838

Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging.

Fabio Minutoli1, Massimo Russo2, Gianluca Di Bella2, Riccardo Laudicella3,4, Alessandro Spataro1, Antonio Vento1, Alessio Comis1, Luca Gentile2, Anna Mazzeo2, Giuseppe Vita2, Sergio Baldari1.   

Abstract

OBJECTIVES: Although expert consensus recommendations suggest 2-3 h as the time interval between bone-seeking radiotracers injection and acquisition, it has been reported that images obtained early after [99mTc]Tc-HMDP administration are sufficient to diagnose cardiac amyloidosis. We evaluated the diagnostic performance of [99mTc]Tc-DPD early phase whole body scan with respect to late phase imaging.
METHODS: We qualitatively and semiquantitatively reviewed [99mTc]Tc-DPD imaging of 53 patients referred for suspect cardiac amyloidosis. Findings of early and late phase images were compared with SPECT results (considered the standard-of-reference) determining sensitivity and specificity for visual analysis of each phase imaging and for each semiquantitative index.
RESULTS: SPECT imaging was negative for cardiac accumulation in 25 patients and positive in 28. Visual analysis of early phase whole body scan had an extremely significant capability to predict SPECT results; nevertheless, complete agreement was not reached. Visual analysis of late phase imaging showed slightly better results. Semiquantitative analysis of early phase images, namely heart to mediastinum ratio, performed better than semiquantitative analysis of late phase images.
CONCLUSION: Visual analysis of [99mTc]Tc-DPD early phase whole body scan is promising in diagnosing cardiac amyloidosis; further studies are needed to confirm our results in different clinical scenarios. KEY POINTS: • Visual analysis of early phase planar imaging using [99mTc]Tc-DPD is accurate to diagnose cardiac amyloidosis and may be satisfactory at least in frail patients with high cardiac burden of amyloid fibrils.
© 2021. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Amyloidosis; Cardiomyopathies; Radionuclide Imaging

Mesh:

Substances:

Year:  2022        PMID: 35031838     DOI: 10.1007/s00330-021-08420-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  3 in total

1.  Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation.

Authors:  F Minutoli; G Di Bella; A Mazzeo; R Laudicella; L Gentile; M Russo; G Vita; S Baldari
Journal:  J Nucl Cardiol       Date:  2019-11-18       Impact factor: 5.952

2.  Cardiac amyloidosis detection by early bisphosphonate (99mTc-HMDP) scintigraphy.

Authors:  M F Santarelli; D Genovesi; V Positano; R Di Sarlo; M Scipioni; A Giorgetti; L Landini; P Marzullo
Journal:  J Nucl Cardiol       Date:  2020-06-28       Impact factor: 5.952

Review 3.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  Circ Cardiovasc Imaging       Date:  2021-07-01       Impact factor: 7.792

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.